专业监测看板

12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)

药物 / 成分：Trastuzumab、Docetaxel

登记的停止原因（原文）：Due to slower than anticipated enrollment, the study was terminated early after 78 patients were recruited.

Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

药物 / 成分：Nivolumab、Ipilimumab、Carboplatin、Paclitaxel

登记的停止原因（原文）：Slow Accrual

A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

药物 / 成分：LY3541860、Placebo

登记的停止原因（原文）：The interim analysis data failed to demonstrate the intended treatment effect.

A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis

药物 / 成分：BI 1839100、Placebo

YN001-004 in Patients With Coronary Atherosclerosis in Australia

药物 / 成分：Dose 1 YN001、Dose 2 YN001、Evolocumab

登记的停止原因（原文）：The study was terminated at the request of the Sponsor.

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

药物 / 成分：Olaparib、Durvalumab、EKG、Tumor biopsy

登记的停止原因（原文）：Closed due to slow accrual.

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

药物 / 成分：BL-M17D1

登记的停止原因（原文）：The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the investigational product's toxicity considerations.

Intraoperative Parathyroid Gland (PTG) Identification Using a Hand-Held Imager (HHI)

药物 / 成分：Parathyroid auto-fluorescence imaging、Indocyanine green

登记的停止原因（原文）：The NIH-funded project period has come to an end.

Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer

药物 / 成分：Zolinza (vorinostat), vinorelbine

Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer

药物 / 成分：Niraparib、Osimertinib

登记的停止原因（原文）：Slow accrual.

A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome

药物 / 成分：Dupilumab Prefilled Syringe、Placebo Prefilled Syringe

登记的停止原因（原文）：no more patients corresponding to the criteriae

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

药物 / 成分：Part 1 Blinded - AL001、Part 1 Blinded - Placebo、Part 2 (OLE Treatment) - AL001、Part 2 (OLE Treatment) - Placebo Switched to AL001

登记的停止原因（原文）：The trial did not meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating® plus National Alzheimer's Coordinating Center Frontotemporal Lobar Degeneration Sum of Boxes (CDR® plus NACC FTLD-SB)

GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL

药物 / 成分：Cohort 1, GNR-084、Cohort 2, GNR-084、Cohort 3, GNR-084、Cohort 4, GNR-084

登记的停止原因（原文）：The sponsor discontinued the development of the drug for reasons other than safety.

A Phase 1 Study of Autologous Dendritic Cell Immunotherapy in Patients With mCRPC

药物 / 成分：Cellgram-DC-PC

登记的停止原因（原文）：Difficulties in patient recruitment.

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

药物 / 成分：Acasunlimab、Pembrolizumab

登记的停止原因（原文）：Genmab has decided to discontinue further clinical development of acasunlimab following strategic portfolio prioritization. The decision was not related to safety concerns.

A Study of LY3549492 in Healthy Weight Adult Participants

药物 / 成分：LY3549492、Placebo

登记的停止原因（原文）：Study terminated for strategic business reasons

Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus

药物 / 成分：Rifampin、No rifampin

登记的停止原因（原文）：After reviewing the recruitment to date as well as considering the anticipated ongoing recruitment challenges and feasibility, the decision was made to close the study.

Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin

药物 / 成分：MBX-102、Placebo、Actos、Metformin

登记的停止原因（原文）：MBX-102 did not meet the target efficacy profile of HbA1c change.

Continuous IntraVenous Infusion of Ketamine in Terminally Ill Cancer Patients

药物 / 成分：Ketamine

登记的停止原因（原文）：The study was terminated early due to the principal investigator's transition to another institution.

RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

药物 / 成分：RVU120(SEL120)

登记的停止原因（原文）：RPD2 has been identified